Mounjaro GoodRx vs Savings Card: Which Is Cheaper in 2026?

Mounjaro GoodRx vs the savings card: the short answer

Start with the indication, because it decides more of your cost than any coupon does. Mounjaro was approved by the FDA in May 2022 to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Insurers, including federal programs, treat a diabetes drug as a standard therapeutic class. The GLP-1 medicines approved only for weight management sit in a category that many plans carve out entirely. Same molecule in Mounjaro and Zepbound, very different coverage behavior, because the approved use differs.

With that settled, the price question splits three ways. If you have commercial insurance and your plan covers Mounjaro, the Lilly savings card is the cheapest route, down to as little as $25 per month per mounjaro.lilly.com, checked on 1 September 2026. If you're paying cash, the contest is between a GoodRx retail coupon and Lilly's own LillyDirect pharmacy, and LillyDirect is far cheaper on the figures available. If you are on Medicare, Medicaid, or TRICARE, the manufacturer card is off the table by its own terms, but your program may well pay for the drug under its diabetes benefit.

One caveat runs through everything below. GoodRx sets prices per pharmacy and per ZIP code, and the coupon figure here comes from a snapshot of GoodRx's own Mounjaro page taken on 1 September 2026. An earlier snapshot published on our full cost guide in April 2026 put the coupon range nearer $900 to $1,100. Both are plausible readings of a price that floats. Pull a live quote for your dose and location rather than treating either number as fixed.

Four figures, four different eligibility gates. Dates on each are given in the text.

How the Mounjaro savings card works

Eligibility and the $25 per month floor

The Lilly savings card is a copay reduction, not a standalone discount. It attaches to a commercial insurance claim that has already been approved for Mounjaro and lowers what you hand over at the pharmacy counter. Lilly states the resulting cost can be as low as $25 per month for patients whose commercial plan covers the drug, per mounjaro.lilly.com as checked on 1 September 2026. The card program runs through 31 December 2026. Prior authorization, where your insurer requires one, is a condition set by the plan rather than by Lilly, and the card cannot stand in for it.

Two tiers: $1,950 a year with coverage, a $499 floor without

This is the pair of numbers people most often mix up, so take them one at a time.

Tier one, your commercial plan covers Mounjaro. The card contributes up to $150 on a 1-month fill, $300 on a 2-month fill, and $450 on a 3-month fill, with a separate maximum of up to $1,950 per calendar year. Your cost lands at $25 as long as the contribution needed stays inside those caps. Above them, you pay the difference.

Tier two, you have commercial insurance but the plan does not cover Mounjaro. A second tier applies, with a floor of $499 per fill, monthly savings of up to $647, and up to $8,411 in annual savings. This tier still requires commercial insurance to exist. It just doesn't require that insurance to cover Mounjaro. Fully uninsured patients are outside the card program entirely and should price LillyDirect instead.

Both tiers sit in the same terms block on mounjaro.lilly.com/savings-coverage and were checked there on 1 September 2026. Our Mounjaro savings card guide walks through enrollment and the pharmacy rejections people run into.

Who the card excludes, and what that does not mean

The test is enrollment, not who pays. Lilly's terms require that you are not enrolled in any state, federal, or government funded healthcare program, naming Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, and TRICARE. Being enrolled in Medicare and choosing to pay cash does not put you back inside the program. Two other limits sit in the same block: the card covers only the Mounjaro single-dose pen, because other methods of administration are not eligible, and it works for a maximum of 13 fills per calendar year, which is what makes the $1,950 annual ceiling line up with 13 fills at the $150 monthly cap.

Mounjaro GoodRx pricing, and what the coupon actually does

What the coupon is running

On 1 September 2026, GoodRx's Mounjaro page advertised the drug from $1,086.78 for the most common version, described as roughly 19% off an average retail price of $1,348.16. For context, Lilly's published list price for Mounjaro is $1,112.16 for a 28-day supply (mounjaro.lilly.com FAQ, checked October 2, 2026), so the GoodRx figure sits slightly below list.

GoodRx coupon against LillyDirect self-pay

For a cash payer, this is the comparison that matters, and it isn't close. LillyDirect, Lilly's own direct pharmacy channel, lists self-pay pricing starting at $499 per month for the single-dose prefilled pen, and it shows that same starting figure on every strength from 2.5 mg through 15 mg (lilly.com/lillydirect/mounjaro, checked 1 September 2026). Lilly words it as a starting price and notes that taxes and fees may apply, so read $499 as a floor rather than a fixed bill. Even so, against a GoodRx coupon near $1,086.78 the direct channel starts several hundred dollars a month lower at every dose.

The reason is structural rather than promotional. A GoodRx coupon lowers what a retail pharmacy charges, and that price still carries the pharmacy's acquisition cost and margin. LillyDirect ships from the manufacturer's own dispensing channel, so the retail layer is not in the chain. If you're paying cash, price LillyDirect first and treat GoodRx as the comparison. Our LillyDirect Mounjaro guide covers eligibility and how the ordering flow works.

One label to keep straight while you shop: $499 turns up in more than one place in Mounjaro's pricing world, and two of them matter here. One is the LillyDirect self-pay monthly price for a cash payer. The other is the savings card's tier-two per-fill floor for someone with commercial insurance that does not cover the drug. Different programs, different eligibility, same number by coincidence.

Why a coupon cannot be stacked on insurance

Lilly's own terms rule it out: card savings cannot be combined with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Mounjaro. The mechanics agree. A pharmacy processes one payment pathway per fill, either billing your insurer and applying the card to what is left, or running the fill as a cash transaction at the coupon price. The practical move is to price both pathways separately for your dose, then hand the pharmacist whichever one is lower.

Which eligibility class you are actually in

Four situations, four different answers. Find yours before you compare any numbers.

• Commercial insurance, plan covers Mounjaro. Use the savings card. Ask your insurer what your Mounjaro copay is on your tier, then check it against the card's caps of $150 per 1-month fill and $1,950 a year. In this class the card is normally far cheaper than any coupon.
• Commercial insurance, plan excludes Mounjaro or the prior authorization was denied. The card's tier-two terms apply, at a $499 per-fill floor with up to $8,411 in annual savings. Price that against LillyDirect self-pay starting at $499 per month and a live GoodRx quote, since all three land in similar territory and the tie-breaker is usually shipping and convenience.
• Medicare, Medicaid, or TRICARE. The manufacturer card is unavailable to you. Go straight to your program's diabetes drug benefit, because Mounjaro's type 2 diabetes indication is the reason it can be covered there at all. The next section walks through each one.
• Uninsured or paying cash by choice. The savings card requires commercial insurance, so it is out. Start with LillyDirect self-pay, which starts at $499 per month, and use a live GoodRx quote as your comparison.

Card eligibility and program coverage are answered on separate branches.

Medicare, Medicaid, and TRICARE cover Mounjaro for type 2 diabetes, with conditions

Medicare Part D

Part D plans can cover Mounjaro because it is prescribed for an FDA-approved indication, type 2 diabetes. Permitted is not the same as automatic: coverage depends on your specific plan's formulary, the tier it places the drug on, and prior authorization, which is common for GLP-1 medicines. Check your plan's formulary for the current year rather than assuming last year's answer still holds.

The cost protection that matters most on Part D is the annual out-of-pocket cap introduced by the Inflation Reduction Act redesign. It started at $2,000 when the redesign took effect on 1 January 2025, and it is indexed, so it climbs each year: for 2026 the ceiling is $2,100, and for 2027 it is $2,400 (medicare.gov, checked 2 October 2026). Once your out-of-pocket spending on covered Part D drugs reaches it, you pay nothing more for those drugs that year. Part D's statutory exclusion of weight-loss agents, at Social Security Act section 1860D-2(e)(2)(A), turns on the indication a drug is prescribed for rather than the molecule itself, which is why the same active ingredient can be covered for one approved use and excluded for another. Our Wegovy GoodRx comparison covers that side of it.

TRICARE

TRICARE is the clearest illustration of why the indication decides the outcome. Its pharmacy program FAQ, last updated 6 August 2026, states plainly: "TRICARE covers Trulicity, Ozempic, Victoza and Mounjaro to treat type 2 diabetes." Access is conditional rather than automatic: you have to meet TRICARE's clinical criteria, and your provider has to complete prior authorization and medical necessity forms. TRICARE does not publish a Mounjaro copay amount on that page, though it notes Trulicity carries a lower copayment, so check your own plan for the exact cost-share.

Set that against how the same program treats weight-loss GLP-1s, where the FAQ says: "You will pay 100% of the cost for your weight loss drugs even if you have an approved prior authorization." An approved prior authorization on a weight-loss GLP-1 buys access, not a subsidy. Mounjaro prescribed for type 2 diabetes does not sit in that carve-out. If you're a TRICARE beneficiary with a diabetes diagnosis, the savings card exclusion is close to irrelevant, because your pharmacy benefit is the better route anyway.

Don't generalize this in either direction. It is a statement about Mounjaro for type 2 diabetes, not about tirzepatide in every use. The same molecule prescribed for weight management under a different brand falls under the weight-loss policy above, which is why the two brands need separate answers. Our Mounjaro vs Zepbound comparison lays out where the two diverge.

Medicaid

State Medicaid programs participating in the federal drug rebate program are required to cover drugs for their FDA-approved indications, which brings Mounjaro for type 2 diabetes within scope. In practice, prior authorization and state-specific formulary placement still gate access, and step therapy through older diabetes agents is common. Coverage for weight-loss use without a diabetes diagnosis is optional for states and varies widely, a pattern KFF documented in its 2024 review of Medicaid GLP-1 coverage. Check your own state program for its current criteria.